Cidara Therapeutics, Inc.
CDTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -94.5% | -63.9% | 30% | – |
| Gross Profit | $0 | -$0 | $0 | -$0 |
| % Margin | 100% | -57.9% | 100% | -47.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -13,793.6% | -115.7% | -51.8% | -84.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -13,319.8% | -98.5% | -52.1% | -85.7% |
| EPS Diluted | -26.75 | -5.25 | -9.61 | -16.19 |
| % Growth | -409.5% | 45.4% | 40.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |